Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Affiliations

• ¹ MD Anderson Cancer Center, University of Texas, Houston, TX, USA. miwang@mdanderson.org.
• ² Plymouth University Medical School, Plymouth, UK.
• ³ Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
• ⁴ John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
• ⁵ CHU Dijon - Hôpital d'Enfants, Dijon, France.
• ⁶ Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
• ⁷ Institut d'Hématologie de Basse-Normandie, Caen, France.
• ⁸ Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands.
• ⁹ CHU de Rennes, Rennes, France.
• ¹⁰ Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000, Lille, France.
• ¹¹ Clínica Universidad de Navarra, Pamplona, Spain.
• ¹² Moffitt Cancer Center, Tampa, FL, USA.
• ¹³ Cancer Research UK Centre, University of Southampton Faculty of Medicine, Southampton, UK.
• ¹⁴ Border Medical Oncology, Albury, Victoria, Australia.
• ¹⁵ Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France.
• ¹⁶ Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
• ¹⁷ Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, HOVON Lunenburg Lymphoma Phase I/II Consortium, Amsterdam, Netherlands.
• ¹⁸ CHU de Nantes-Hotel Dieu, Nantes, France.
• ¹⁹ Institut Universitaire du Cancer-Oncopole Toulouse (IUCT-O), Toulouse, France.
• ²⁰ Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.
• ²¹ MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
• ²² Acerta Pharma, South San Francisco, CA, USA.
• ²³ Department of Haematology, Jagiellonian University, Krakow, Poland.